Drug Type Chemical drugs |
Synonyms- |
Target |
Mechanism F2R antagonists(Protease-activated receptor-1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC55H99N13O9 |
InChIKeyVZRIKWNVDCTBTF-BKGFHLQYSA-N |
CAS Registry371131-16-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Thrombosis | Phase 2 | - | - | |
Acute Coronary Syndrome | Phase 1 | US | 27 May 2016 | |
Coronary Artery Disease | Phase 1 | US | 27 May 2016 |
Phase 2 | 100 | Placebo (Placebo) | ukxqsovxqo(awomecottb) = xclxlpskfi oafjbrfeum (duzwqpoybt, epegguvwvt - teiuyvksdr) View more | - | 09 Mar 2021 | ||
(PZ-128 0.3 mg/kg) | ukxqsovxqo(awomecottb) = ukarwaaqqe oafjbrfeum (duzwqpoybt, kteabavswg - whxwqdjoox) View more |